Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID-19 severe or critically meta-analysis

HYDRA, 2020
 
NCT04315896
RCThydroxychloroquineplaceboCOVID-19 severe or criticallyNA
75/77 inconclusive -1%
REMAP-CAP-HCQ, 2020
 
NCT02735707
RCThydroxychloroquinestandard of careCOVID-19 severe or criticallyNA
61/81 inconclusive 4%
Mahevas, 2020 OBShydroxychloroquinestandard of careCOVID-19 severe or criticallyserious
84/97 inconclusive -35%
Yu, 2020 OBShydroxychloroquinecontrolCOVID-19 severe or criticallycritical
48/520 suggested -61%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).